Thrombocytopenia and coronavirus: A prognosis and progression of the Coronavirus disease

Kazem Ansari; Ehsan Ghemtiri; Shima Hamidipour; Shirin Saberianpour

doi:10.18502/ijpho.v12i2.9078

Kazem Ansari Nano-biotech Foresight Company, Biotechnology Campus, Yazd Stem Cells and Regenerative Medicine Institute, Yazd, Iran.
Ehsan Ghemtiri Department of Radiology, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Shima Hamidipour Pediatrician Neonatologist, Isfahan University of Medical Sciences, Isfahan, Iran.
Shirin Saberianpour Vascular and endovascular surgery research center, Mashhad University of Medical Sciences, Mashhad, Iran.

DOI: https://doi.org/10.18502/ijpho.v12i2.9078

Keywords: Covid-19, Platelets, Thrombocytopenia

Abstract

Coronavirus pneumonia has been detected in Wuhan City since December 2019. Today, coronavirus 2019 (COVID-19) has become an epidemic worldwide. Although this disease is not fully understood, it can show different symptoms over time. One of the components involved in the body by this virus is platelets that communicate directly with several different types of viruses, including the SARS-CoV virus family, via integrins, P-selectins, and pseudo-receptors. Mechanism of action includes the virus's direct effect on bleeding and maturation of megakaryocytes, increased adhesion and activation of platelets, and platelet consumption in abscesses of damaged lung tissue. Therefore, Covid-19 disease can affect platelet function, which in itself can directly or indirectly affect thrombocytopenia. Pathology of bone marrow aspiration from three patients with Covid-19 thrombocytopenia indicates abnormal megakaryocyte maturation. In addition, it can be associated with the severity and mortality of the disease. In other words, thrombocytopenia can be used as a prognostic factor in patients with progressive Covid- 19, which has been reported in 5 to 40% of COVID-19 patients. This study attempts to gather information and recent reports on thrombocytopenia in patients with Covid-19.